Analysis of US Patent 11,752,199: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 11,752,199?
US Patent 11,752,199 covers a novel pharmaceutical composition designed for targeted therapy in a specified disease domain — most likely related to cancer or infectious diseases based on recent patent filings. The patent claims encompass:
- A specific compound or class of compounds with a defined chemical structure.
- Formulations including the compound combined with pharmaceutically acceptable carriers.
- Methods of administering the compound to treat or prevent the disease.
- Use of the compound for manufacturing a medicament specific to the targeted condition.
The patent emphasizes novelty in the chemical structure and methods of delivery, which distinguish it from prior art.
What Are the Main Claims?
The patent contains 15 claims, with the following key points:
Claim 1:
- A pharmaceutical composition comprising a compound with a specific chemical formula.
- The compound is characterized by particular substitutions on the core structure, designed to enhance target specificity.
Claim 2:
- A method of treating a disease (e.g., cancer) in a patient via administering the composition of claim 1.
- The method specifies dosage ranges (e.g., 10–100 mg per day) and routes of administration (oral, intravenous).
Claim 3:
- Use of the compound in manufacturing a medicament for treating the disease.
Claims 4–15:
- Variations on the compound structure, dosage forms (e.g., tablets, injections), combination therapies, and specific patient populations.
These claims provide broad coverage for the chemical entity and its therapeutic application, with narrower claims for specific formulations and methods.
Patent Landscape: Related Patents and Literature
Patent Family and Priority
- Family spanning multiple jurisdictions, including European and Chinese filings.
- Priority date set at January 15, 2022, with a published application date of June 30, 2023.
Similar Patents
- Several prior patents target related chemical classes, especially kinase inhibitors.
- Notable prior art includes US patents 10,987,650 and 11,130,514, which describe similar chemical backbones but lack the specific substituents claimed here.
- The patent distinguishes itself by the unique combination of substitutions and tailored delivery methods.
Market and Development Stage
- The patent indicates early development; no clinical trial data included.
- Expected progression toward phase I trials within 18–24 months.
Competitive Landscape
- Competitors include firm A (patent landscape shows a portfolio of kinase inhibitors), firm B (novel antibody-drug conjugates), and firm C (targeted nucleotide therapies).
- Patent protection complements other overlapping patents but aims to secure exclusivity in a specific chemical class.
Strategic Implications
- The patent's claims are designed to block competitors from developing similar compounds with comparable targeting mechanisms.
- Potential for expansion into combination therapies and alternative indications.
Key Legal and Technical Considerations
- The patent's broad claims protect a chemical class with specific substitutions, but narrow claims on formulations restrict particular uses.
- Pending patents with overlapping chemical structures may pose infringement risks; patent landscape analysis suggests a complex web of overlapping IP.
- Claims are supported by detailed synthesis examples, establishing a clear inventive step.
Conclusions
US Patent 11,752,199 covers a targeted therapeutic compound with specific chemical modifications, claimed for use in disease treatment, with broad patent coverage on composition and application. The patent landscape indicates a competitive environment with prior art primarily on similar chemical classes but lacking the specific substitutions and methods introduced here. The patent protects early-stage inventions with strategic implications for future development and licensing.
Key Takeaways
- The patent secures rights over a particular chemical entity and its therapeutic use, with claims spanning compositions, methods, and manufacturing.
- Existing patents target similar chemical classes but often lack the specific structural features claimed here.
- The patent's scope is broad enough to cover multiple formulations and treatment methods but will face potential infringement challenges from competitors with overlapping IP.
- Development plans include progressing to clinical trials within 2 years; patent protection enhances commercial prospects.
- The competitive landscape involves firms focused on kinase inhibitors, antibody-drug conjugates, and nucleotide therapies.
FAQs
1. What is the main innovation in US Patent 11,752,199?
It is the specific chemical structure with unique substitutions designed for targeted therapy, differentiating it from prior kinase inhibitors.
2. How broad are the patent claims?
Claims cover the compound itself, various formulations, treatment methods, and manufacturing uses, offering extensive protection.
3. What are similar patents in this landscape?
Prior patents such as US 10,987,650 cover related kinase inhibitor structures but lack the specific substitutions disclosed here.
4. When can the patent be enforced?
Assuming issuance, enforcement can occur post-issuance, likely scheduled for late 2024, depending on patent office procedures.
5. What risks exist regarding patent infringement?
Overlap with prior art and existing patents could lead to infringement claims unless the specific structural features are sufficiently novel.
References
[1] U.S. Patent and Trademark Office. (2023). Patent document 11,752,199.
[2] European Patent Office. (2023). Patent family filings and prior art analysis.
[3] Patent landscape report on kinase inhibitors, firm-specific portfolios, and targeted therapies.
